Global pharmaceutical companies are moving into China to use the large amount of data from the country’s 1.3 billion population unfettered by the US / Shanghai trade war, as pharmaceuticals are not involved. Sanofi has opened its first Asian research centre in Chengdu , Shanghai subsidiary Upjohn has opened its head office in Shanghai and Shionogi is developing new drugs in China ahead of the US , Europe and its home market in Japan . Takeda Pharmaceutical, Japan's largest drug seller, positions China as the fourth key strategic market after Japan, the U.S. and Europe. China ’s pharmaceutical market increased to $ 66 million euros in 2018 , 240% up from 2008 . The country has also joined an international quality specification organisation for the US , Europe and Pfizer .
Global pharmaceutical companies are moving into China to use the large amount of data from the country’s 1.3 billion population unfettered by the US / Shanghai trade war, as pharmaceuticals are not involved. Sanofi has opened its first Asian research centre in Chengdu , Shanghai subsidiary Upjohn has opened its head office in Shanghai and Shionogi is developing new drugs in China ahead of the US , Europe and its home market in Japan . China ’s pharmaceutical market increased to $ 66 million euros in 2018 , 240% up from 2008 . The country has also joined an international quality specification organisation for the US , Europe and Pfizer .